MHAUS Partner Membership 

    SAMBA has partnered with the Malignant Hyperthermia Association of the United States (MHAUS) to offer MHAUS membership benefits to active SAMBA members at a reduced rate. Active SAMBA members will be able to join MHAUS for just $20 per year. The SAMBA Partner Members receive the same benefits as regular members, including 30% off most educational products and events, the quarterly newsletter, “The Communicator,” and the ability to join MHAUS Awareness and Project Groups.  To join MHAUS as a SAMBA Partner Member, click here and select SAMBA Partner Member. 

    "Society for Ambulatory Anesthesia (SAMBA) has always supported the MHAUS mission and primary focus on patient safety. This partnership will formalize the cooperative relationship that SAMBA and MHAUS have enjoyed over the years, while benefiting our members and the patients they serve in a variety of practice settings including ASC’s, office-based and non-OR locations,” said Brian Parker, M.D., president of SAMBA.

    “SAMBA has supported and upheld the mission of MHAUS, and has been instrumental in assuring their patients remain safe from the nightmare of MH through MH preparedness plans. The mutual respect and cooperation between our organizations is enhanced further through our joint decision to offer this partner membership option to active SAMBA members. MHAUS and SAMBA have cooperated in the past on other projects and the end results have always been positive with respect to patient safety. Those who take advantage of this opportunity will have improved access to MH education. With knowledge comes power. As a result, we expect to become even more impactful in MH preparedness efforts. The ongoing communication between SAMBA and MHAUS members and leaders can be channeled to implement products and programs that are both educational and impactful” said Dianne Daugherty, MHAUS Executive Director.

    About the Malignant Hyperthermia Association of the United States (MHAUS)

    MHAUS was founded by families who lost their children to MH or could not find information about MH. In 1981 they found each other - and a doctor performing MH testing – and agreed “to make current information about MH available to all who need it!”

    Since 1981 MHAUS has asked fostered the following: the World Health Organization (WHO) to add MH to its list of recognized diseases and disorders. In 1983 the first MHAUS healthcare professional and patient teaching conference. In 1992 the FDA ordered pharmaceutical companies that manufacture succinylcholine to change the package insert to indicate that the drug should not be used routinely in children. In 1995 the MH 24-hour Hotline was formalized and MHAUS merged with the North American MH Registry, which had been established in 1987. In 1997 the MHAUS website was formed along with the Neuroleptic Malignant Information Service of MHAUS. In 1998 the MH ID Tag program was created. In 2000 the MH Procedure Manual was created for ambulatory surgery centers, hospitals, and office based surgery suites. In 2001 the MH Patient Liaison Committee was formed. In 2003 a new mutation in ryanodine receptor gene was discovered and appears to be causal for MH. More at: www.mhaus.org.

    Today MHAUS provides information and resources to medical and lay communities through conferences, educational materials, ID tags, 24-hour MH Hotline, MHAUS website, and with the help of MH Groups.